# A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

> **NCT03253263** · PHASE2 · RECRUITING · sponsor: **OHB Neonatology Ltd.** · enrollment: 338 (estimated)

## Conditions studied

- Bronchopulmonary Dysplasia
- Chronic Lung Disease of Prematurity
- Intraventricular Hemorrhage
- Retinopathy of Prematurity (ROP)

## Interventions

- **DRUG:** OHB-607

## Key facts

- **NCT ID:** NCT03253263
- **Lead sponsor:** OHB Neonatology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-09
- **Primary completion:** 2026-01-23
- **Final completion:** 2028-01-21
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253263, "A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03253263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*